INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

Cyclin-dependent kinases 4 and 6 (CDK4/6) represent a major therapeutic vulnerability for breast cancer. The kinases are clinically targeted via ATP competitive inhibitors (CDK4/6i); however, drug resistance commonly emerges over time. To understand CDK4/6i resistance, we surveyed over 1,300 breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qing, Jiang, Baishan, Guo, Jiaye, Shao, Hong, Del Priore, Isabella S., Chang, Qing, Kudo, Rei, Li, Zhiqiang, Razavi, Pedram, Liu, Bo, Boghossian, Andrew S., Rees, Matthew G., Ronan, Melissa M., Roth, Jennifer A., Donovan, Katherine A., Palafox, Marta, Reis-Filho, Jorge S., de Stanchina, Elisa, Fischer, Eric S., Rosen, Neal, Serra, Violeta, Koff, Andrew, Chodera, John D., Gray, Nathanael S., Chandarlapaty, Sarat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831444/
https://www.ncbi.nlm.nih.gov/pubmed/34544752
http://dx.doi.org/10.1158/2159-8290.CD-20-1726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831444/
https://www.ncbi.nlm.nih.gov/pubmed/34544752
http://dx.doi.org/10.1158/2159-8290.CD-20-1726

Ejemplares similares